Joint Open Laboratory Established In China by Waters & the Chinese Pharmacopeia Commission

Analytical lab will serve as a national technical support center advancing standardization and screening.
BEIJING, Jan. 28, 2015 /PRNewswire/ -- Waters® Corporation (NYSE: WAT) recently announced the inauguration of its Joint Open Laboratory established together with the Chinese Pharmacopeia Commission (ChP) during an opening ceremony held in Beijing.

The analytic laboratory will be jointly operated by ChP and Waters®. Focus areas include in-depth research of pharmacopoeia standards, development of testing methods, methods validations and basic and advanced technical training of pharmacopoeia detection methods. The laboratory is also anticipated to play a role as one of the national technical support centers in the field of Chinese pharmaceutical standards.

Speaking at the ceremony, Mike Harrington, Vice President of Waters Asia Pacific and European Operations, noted, "Our cooperation with ChP to open and operate this cooperative laboratory in China reflects our commitment to consistently push the boundaries of what's possible by helping to bring more resources to bear that enable innovations in China's pharmaceutical and biopharma industries."

"Our cooperation will meet the needs of ChP's development, while also responding to the demands of even further enhancements to pharmacopoeia standards and improved public drug safety," said Secretary General Zhang Wei of the ChP.

The joint open lab spans 400 square meters and is located within the laboratory building of the Beijing Zhendong Guangming Drug Research Institute. Outfitted with Waters'® chromatography and mass spectrometry technologies, the facility is set to support Pharmacopeia standards in China.

The opening ceremony, hosted by ChP, included officials from China's pharmacopeia supervisory bodies, industry professionals and technicians, and representatives from Chinese pharmaceutical enterprise reviewing future construction and operation prospects for the lab.

For more information: http://www.waters.com

About Waters Corporation (www.waters.com)

For over 50 years, Waters Corporation (NYSE:WAT) has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, water quality, consumer products, and high value-added chemicals. worldwide. Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success. With revenue of $1.9 billion in 2013, Waters is driving scientific discovery and operational excellence for customers worldwide.

About Chinese Pharmacopeia Commission

Commonly referred to as ChP, the Chinese Pharmacopeia Commission is an official and authoritative compendium of drugs and has been in place since 1950 - publishing compendiums in 1953, 1963, 1977, 1985, 1990, 1995, 2000, 2005, and 2010. Formerly reporting under the Chinese Ministry of Health, it is now is an affiliated commission of the newly formed Chinese Food and Drug Administration (CFDA). The Chinese Pharmacopeia Commission is also officially recognized by the World Health Organization.

Waters, ACQUITY, UPLC, and UltraPerformance LC are trademarks of Waters Corporation.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/joint-open-laboratory-established-in-china-by-waters--the-chinese-pharmacopeia-commission-300026899.html

SOURCE Waters Corporation

Jeff Tarmy, +1-508-482-2268, [email protected]

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.